US 12,264,368 B2
Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
Alka Potdar, Cumming, GA (US); Dermot P. McGovern, Los Angeles, CA (US); Janine Bilsborough, Simi Valley, CA (US); and Stephan Targan, Santa Monica, CA (US)
Assigned to CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Appl. No. 17/258,133
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
PCT Filed Jul. 2, 2019, PCT No. PCT/US2019/040394
§ 371(c)(1), (2) Date Jan. 5, 2021,
PCT Pub. No. WO2020/010139, PCT Pub. Date Jan. 9, 2020.
Claims priority of provisional application 62/786,207, filed on Dec. 28, 2018.
Claims priority of provisional application 62/694,935, filed on Jul. 6, 2018.
Prior Publication US 2021/0277477 A1, Sep. 9, 2021
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 10 Claims
 
1. A method of treating an inflammatory bowel disease, the method comprising:
a) identifying a presence of a risk genotype predictive of inflammatory bowel disease (IBD) in a subject by assaying a sample obtained from the subject to detect the presence of the risk genotype, the risk genotype comprising a single nucleotide polymorphism (SNP) selected from the group consisting of an “A” at rs7958372, a “C” at rs2877453, an “A” at rs71327010, a “C” at rs1169302, a “G” at rs1169303, an “A” at rs6519183, a “C” at rs685548, an “A” at rs11998187, an “A” at rs531819, a “G” at rs1041968, a “G” at rs693, an “A” at rs512535, a “G” at rs550619, an “A” at rs570877, a “G” at rs12713956, an “A” at rs2301723, an “A” at rs2499714, an “A” at rs6583176, an “A” at rs369880, a “G” at rs57884093, an “A” at rs989690, an “A” at rs7704116, an “A” at rs12984273, a “G” at rs16891235, a “C” at rs7296651, an “A” at is rs516535, an “A” at rs9276427, an “A” at rs296564, an “A” at rs296569, an “A” at rs296568, a “G” at rs296567, a “G” at rs296561, a “G” at rs72749142, an “A” at rs9291547, an “A” at rs10761532, an “A” at rs10821813, a “C” at rs1561852, an “A” at rs10994464, a “G” at rs993402, an “A” at rs10994467, an “A” at rs10821822, a “G” at rs1837949, a “C” at rs35597961, a “G” at rs10821830, an “A” at rs975262, an “A” at rs973067, a “G” at rs10509139, an “A” at rs1442539, an “A” at rs2197155, a “G” at rs7919914, a “G” at rs10994476, an “A” at rs35471473, a “G” at rs12785023, a “G” at rs12783716, a “G” at rs10821821, a “G” at rs10994441, a “C” at rs10994442, a “T” at rs10821814, an “A” at rs10994465, a “T” at rs12218617, a “C” at rs10509138, an “A” at rs61854518, a “G” at rs10821699, a “G” at rs7919274, an “A” at rs 10761552, a “G” at rs17037425, an “A” at rs2893861, a “C” at rs1993939, a “G” at rs10821833, a “G” at rs1904418, a “G” rs16915196, an “A” at rs61853514, an “A” at rs10994430, an “A” at rs16915231, a “G” at rs2028564, a “G” at rs13196552, an “A” at rs17587597, an “A” at rs17587226, an “A” at rs2276917, an “A” at rs10013653, an “A” at rs11582799, an “A” at rs111692854, and an “A” at rs72632053; and
b) administering to the subject a therapeutically effective amount of a therapeutic agent, the therapeutic agent comprising at least one of an inhibitor of phosphodiesterase 4C (PDE4C) activity or expression and an inhibitor or agonist of adenylate cyclase 7 (ADCY7), provided the risk genotype is present in (a).